ÂÜÀòÂÒÂ×

Jing Zhu, Ph.D. has a diverse work experience in biotechnology and pharmaceutical companies. Currently, they hold the position of VP, Nucleic Acid & Viral Vector Technology at Arranta Bio, where they started in March 2023. Prior to this, from August 2022 to April 2023, they served as the VP, Nucleic Acid Technology for the same company.

Before joining Arranta Bio, Jing worked at RVAC Medicines as the Director, mRNA Process and Analytical Development from August 2021 to August 2022.

In 2020, Jing joined Luye Pharma USA Ltd. and held the positions of Associate Director, mRNA Process Development from May 2021 to August 2021, and Principal Scientist, mRNA Process Development from August 2020 to May 2021.

Jing's earlier experience includes roles at Thermo Fisher Scientific. Jing worked as the R&D Manager, Pharm Purification & Analytics from 2018 to 2020, Staff Scientist, Bioproduction Purification from 2015 to 2018, and Scientist III, Bioproduction Purification from 2012 to 2015.

Jing Zhu, Ph.D. obtained a Ph.D. in Nanofibrous membrane for protein purification from the University of California, Davis, between 2007 and 2012. Prior to that, between 2003 and 2007, Zhu completed a B.S. in Chemistry at Donghua University. Additionally, Zhu has obtained a certification as a Certified Six Sigma Black Belt from SixSigma.us in December 2017.